USD 102.13
(0.13%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 835.25 Million USD | -4.44% |
2022 | 874.11 Million USD | 118.89% |
2021 | 399.34 Million USD | 12.3% |
2020 | 355.61 Million USD | 22.07% |
2019 | 291.31 Million USD | -21.02% |
2018 | 368.82 Million USD | 2.29% |
2017 | 360.56 Million USD | -0.51% |
2016 | 362.41 Million USD | -15.26% |
2015 | 427.66 Million USD | -12.51% |
2014 | 488.84 Million USD | -1.61% |
2013 | 496.82 Million USD | -0.19% |
2012 | 497.75 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 885.79 Million USD | 6.05% |
2024 Q2 | 913.14 Million USD | 3.09% |
2023 FY | 835.25 Million USD | -4.44% |
2023 Q3 | 822.85 Million USD | 4.81% |
2023 Q4 | 835.25 Million USD | 1.51% |
2023 Q1 | 903.76 Million USD | 3.39% |
2023 Q2 | 785.07 Million USD | -13.13% |
2022 Q4 | 874.11 Million USD | 90.9% |
2022 Q2 | 446.49 Million USD | 6.99% |
2022 Q1 | 417.31 Million USD | 4.5% |
2022 FY | 874.11 Million USD | 118.89% |
2022 Q3 | 457.88 Million USD | 2.55% |
2021 FY | 399.34 Million USD | 12.3% |
2021 Q1 | 315.32 Million USD | -11.33% |
2021 Q2 | 349.66 Million USD | 10.89% |
2021 Q3 | 348.47 Million USD | -0.34% |
2021 Q4 | 399.34 Million USD | 14.6% |
2020 FY | 355.61 Million USD | 22.07% |
2020 Q1 | 285.72 Million USD | -1.92% |
2020 Q3 | 366.01 Million USD | 0.52% |
2020 Q4 | 355.61 Million USD | -2.84% |
2020 Q2 | 364.11 Million USD | 27.43% |
2019 Q2 | 298 Million USD | -17.38% |
2019 Q4 | 291.31 Million USD | -3.29% |
2019 FY | 291.31 Million USD | -21.02% |
2019 Q1 | 360.69 Million USD | -2.21% |
2019 Q3 | 301.24 Million USD | 1.09% |
2018 Q4 | 368.82 Million USD | -0.13% |
2018 Q1 | 358.92 Million USD | -0.46% |
2018 FY | 368.82 Million USD | 2.29% |
2018 Q2 | 357.27 Million USD | -0.46% |
2018 Q3 | 369.31 Million USD | 3.37% |
2017 Q4 | 360.56 Million USD | 0.45% |
2017 FY | 360.56 Million USD | -0.51% |
2017 Q3 | 358.93 Million USD | 1.09% |
2017 Q2 | 355.05 Million USD | 1.24% |
2017 Q1 | 350.72 Million USD | -3.23% |
2016 Q4 | 362.41 Million USD | -3.65% |
2016 FY | 362.41 Million USD | -15.26% |
2016 Q1 | 423.48 Million USD | -0.98% |
2016 Q2 | 425.63 Million USD | 0.51% |
2016 Q3 | 376.12 Million USD | -11.63% |
2015 Q3 | 426.27 Million USD | -0.67% |
2015 Q4 | 427.66 Million USD | 0.33% |
2015 Q2 | 429.13 Million USD | -12.36% |
2015 Q1 | 489.63 Million USD | 0.16% |
2015 FY | 427.66 Million USD | -12.51% |
2014 Q4 | 488.84 Million USD | -2.0% |
2014 FY | 488.84 Million USD | -1.61% |
2014 Q1 | 497.73 Million USD | 0.18% |
2014 Q2 | 492.79 Million USD | -0.99% |
2014 Q3 | 498.82 Million USD | 1.22% |
2013 FY | 496.82 Million USD | -0.19% |
2013 Q1 | 507.27 Million USD | 1.91% |
2013 Q3 | 507.08 Million USD | 0.42% |
2013 Q2 | 504.96 Million USD | -0.45% |
2013 Q4 | 496.82 Million USD | -2.02% |
2012 Q4 | 497.75 Million USD | 0.0% |
2012 FY | 497.75 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 11.881% |
Embecta Corp. | 2.03 Billion USD | 58.978% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | -77.084% |
Dynavax Technologies Corporation | 375.02 Million USD | -122.721% |
Esperion Therapeutics, Inc. | 660.79 Million USD | -26.403% |
Pacira BioSciences, Inc. | 704.25 Million USD | -18.601% |
PainReform Ltd. | 2.69 Million USD | -30938.907% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | -409.598% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -13504.42% |
SCYNEXIS, Inc. | 55.45 Million USD | -1406.325% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -8982.226% |
Cosmos Health Inc. | 30.25 Million USD | -2660.95% |
Journey Medical Corporation | 56.49 Million USD | -1378.357% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -13504.42% |
Safety Shot Inc | 3.89 Million USD | -21360.626% |
Alpha Teknova, Inc. | 38.55 Million USD | -2066.629% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | -510.251% |
Bright Green Corporation | 6.43 Million USD | -12873.653% |
Procaps Group, S.A. | 462.06 Million USD | -80.766% |
Theratechnologies Inc. | 98.63 Million USD | -746.782% |
Harrow Health, Inc. | 241.75 Million USD | -245.5% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -9439.253% |
Biofrontera Inc. | 23.13 Million USD | -3509.737% |
DURECT Corporation | 30.4 Million USD | -2647.014% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -71.348% |
Cronos Group Inc. | 43.73 Million USD | -1809.766% |
OptiNose, Inc. | 194.33 Million USD | -329.803% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | -2.189% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1624.135% |
RedHill Biopharma Ltd. | 20.97 Million USD | -3881.562% |
Organogenesis Holdings Inc. | 181.36 Million USD | -360.547% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -22042.824% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1490.475% |
Radius Health, Inc. | 804.29 Million USD | -3.85% |
Universe Pharmaceuticals INC | 13.75 Million USD | -5972.684% |
ProPhase Labs, Inc. | 42.54 Million USD | -1863.278% |
Phibro Animal Health Corporation | 725.54 Million USD | -15.122% |
Procaps Group S.A. | 462.06 Million USD | -80.766% |
Alvotech | 1.88 Billion USD | 55.632% |
TherapeuticsMD, Inc. | 14.02 Million USD | -5856.761% |
Viatris Inc. | 27.21 Billion USD | 96.931% |
Rockwell Medical, Inc. | 30.88 Million USD | -2604.673% |
Aytu BioPharma, Inc. | 90.37 Million USD | -824.172% |
SIGA Technologies, Inc. | 57.97 Million USD | -1340.662% |
Tilray Brands, Inc. | 892.11 Million USD | 6.374% |
Lifecore Biomedical, Inc. | 219.8 Million USD | -280.008% |
Shineco, Inc. | 47.6 Million USD | -1654.68% |
PetIQ, Inc. | 645.22 Million USD | -29.451% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -380406.305% |
Incannex Healthcare Limited | 5.83 Million USD | -14226.878% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 18.064% |
Alimera Sciences, Inc. | 107.35 Million USD | -678.04% |
Silver Spike Investment Corp. | 3 Million USD | -27650.96% |
Assertio Holdings, Inc. | 148.41 Million USD | -462.781% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -43954.452% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -3818.493% |
Clever Leaves Holdings Inc. | 7.02 Million USD | -11788.087% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -9737.512% |
Avadel Pharmaceuticals plc | 173.38 Million USD | -381.73% |
Hempacco Co., Inc. | 18.82 Million USD | -4337.568% |
Talphera, Inc. | 6.29 Million USD | -13179.126% |
Alvotech | 1.88 Billion USD | 55.632% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -383.926% |
Currenc Group, Inc. | 177.67 Million USD | -370.102% |
Kamada Ltd. | 109.96 Million USD | -659.543% |
Indivior PLC | 1.95 Billion USD | 57.194% |
Evoke Pharma, Inc. | 9.64 Million USD | -8557.233% |
Flora Growth Corp. | 17.22 Million USD | -4749.942% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -9737.512% |
Evolus, Inc. | 209.68 Million USD | -298.335% |
HUTCHMED (China) Limited | 536.38 Million USD | -55.719% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 4.377% |
Akanda Corp. | 12.66 Million USD | -6492.98% |